Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risankizumab maintenance and long-term extension study in moderate to severe Crohn's disease responders from M16-006 or M15-991
MOH_2018-02-07_000647Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of risankizumab in Crohn's disease (6 arms), sponsored by AbbVie Inc. Primary endpoint: Primary endpoints not reported in registry entry. Started Dec 2017; status: active, not recruiting.
02
Drugs
risankizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2018-02-07_000647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-02-07_000647.